BENZAZEPINONE CALCIUM-CHANNEL BLOCKERS .4. STRUCTURE ACTIVITY OVERVIEW AND INTRACELLULAR BINDING-SITE

被引:48
|
作者
KIMBALL, SD
FLOYD, DM
DAS, J
HUNT, JT
KRAPCHO, J
ROVNYAK, G
DUFF, KJ
LEE, VG
MOQUIN, RV
TURK, CF
HEDBERG, SA
MORELAND, S
BRITTAIN, RJ
MCMULLEN, DM
NORMANDIN, DE
CUCINOTTA, GG
机构
[1] Bristol-Myers Squibb Pharmaceutical Research Institute, New Jersey 08543-4000, P.O. Box 4000, Princeton
关键词
D O I
10.1021/jm00082a020
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We have synthesized a series of benzazepinones (2) in order to determine the structure-activity relationships (SAR) for calcium channel blockers related to diltiazem. A prerequisite for calcium channel blocking activity in vitro and in vivo is the presence of two pharmacophores: a 4'-aryl methyl ether and a basic substituent appended to N1 with a pK(a) in the physiological range. When these constraints are satisfied, a wide variety of substitution is tolerated at C6, C7, and C3. The presence of an electron-withdrawing group at C6 appears to enhance potency in vitro and in vivo. For such benzazepinones, activity is primarily dependent upon lipophilicity, as measured by log P. We believe these compounds must partition into the cell membrane in order to access their receptor. The quaternary methiodide 15k was used to demonstrate that the binding site for benzazepinones is on the intracellular face of the membrane. This work represents the first comprehensive SAR of diltiazem-like calcium channel blockers.
引用
收藏
页码:780 / 793
页数:14
相关论文
共 50 条
  • [1] TRICYCLIC ANTIDEPRESSANTS AND CALCIUM-CHANNEL BLOCKERS - INTERACTIONS AT THE (-)-DESMETHOXYVERAPAMIL BINDING-SITE AND THE SEROTONIN TRANSPORTER
    REHAVI, M
    CARMI, R
    WEIZMAN, A
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 155 (1-2) : 1 - 9
  • [2] THE INTERACTION OF PHENYLALKYLAMINE CALCIUM-CHANNEL BLOCKERS WITH THE 1,4-DIHYDROPYRIDINE BINDING-SITE
    ZOBRIST, RH
    GIACOMINI, KM
    NELSON, WL
    GIACOMINI, JC
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1986, 18 (09) : 963 - 974
  • [3] BENZAZEPINONE CALCIUM-CHANNEL BLOCKERS .3. SYNTHESIS AND STRUCTURE ACTIVITY STUDIES OF 3-ALKYLBENZAZEPINONES
    DAS, J
    FLOYD, DM
    KIMBALL, SD
    DUFF, KJ
    VU, TC
    LAGO, MW
    MOQUIN, RV
    LEE, VG
    GOUGOUTAS, JZ
    MALLEY, MF
    MORELAND, S
    BRITTAIN, RJ
    HEDBERG, SA
    CUCINOTTA, GG
    JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (04) : 773 - 780
  • [4] A BINDING-SITE MODEL FOR CALCIUM-CHANNEL INACTIVATION THAT DEPENDS ON CALCIUM ENTRY
    STANDEN, NB
    STANFIELD, PR
    PROCEEDINGS OF THE ROYAL SOCIETY SERIES B-BIOLOGICAL SCIENCES, 1982, 217 (1206): : 101 - 110
  • [5] EFFECT OF CALCIUM-CHANNEL BLOCKERS ON INTRACELLULAR CALCIUM ACCUMULATION
    HAAGWEBER, M
    HORL, WH
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1994, 9 : 24 - 27
  • [6] BENZAZEPINONE CALCIUM-CHANNEL BLOCKERS .5. EFFECTS ON ANTIHYPERTENSIVE ACTIVITY ASSOCIATED WITH N1 AND AROMATIC SUBSTITUENTS
    DAS, J
    FLOYD, DM
    KIMBALL, SD
    DUFF, KJ
    LAGO, MW
    KRAPCHO, J
    WHITE, RE
    RIDGEWELL, RE
    OBERMEIER, MT
    MORELAND, S
    MCMULLEN, D
    NORMANDIN, D
    HEDBERG, SA
    SCHAEFFER, TR
    JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (14) : 2610 - 2617
  • [7] FUNCTIONAL DIHYDROPYRIDINE BINDING-SITE ASSOCIATED WITH SLOW CALCIUM-CHANNEL IN RAT CULTURED NEURONS
    MALOTEAUX, JM
    OCTAVE, JN
    LATERRE, EC
    NEUROSCIENCE LETTERS, 1988, 87 (1-2) : 168 - 172
  • [8] INTERACTION OF THE HUMAN-PLATELET PAF-ACETHER BINDING-SITE WITH CALCIUM AND CALCIUM-CHANNEL ANTAGONISTS
    WADE, PJ
    LAD, N
    TUFFIN, DP
    PROGRESS IN LIPID RESEARCH, 1986, 25 : 163 - 165
  • [9] BENZAZEPINONE CALCIUM-CHANNEL BLOCKERS .2. STRUCTURE-ACTIVITY AND DRUG-METABOLISM STUDIES LEADING TO POTENT ANTIHYPERTENSIVE AGENTS - COMPARISON WITH BENZOTHIAZEPINONES
    FLOYD, DM
    KIMBALL, SD
    KRAPCHO, J
    DAS, J
    TURK, CF
    MOQUIN, RV
    LAGO, MW
    DUFF, KJ
    LEE, VG
    WHITE, RE
    RIDGEWELL, RE
    MORELAND, S
    BRITTAIN, RJ
    NORMANDIN, DE
    HEDBERG, SA
    CUCINOTTA, GG
    JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (04) : 756 - 772